Webinar: Developing novel human iPSC models for atrial fibrillation

Atrial Fibrillation (AF) is the most prevalent cardiac arrhythmia. It is a progressive, multifactorial disease, initiating with electrophysiological abnormalities and developing into morphological, structural and substrate pathologies. As the disease mechanisms are not yet fully understood, a lack of effective and lasting treatments continues.
Human-induced pluripotent stem cell (iPSC)-derivatives are a unique tool to improve in vitro investigation of AF disease mechanisms and can help elucidate new treatments. At Ncardia, we recently developed a human iPSC-based AF model to investigate the influence of inflammation and immune cells on atrial arrhythmias.
In this webinar, we will present a new coculture approach, combining human iPSC-derived atrial cardiomyocytes and macrophages to study new underlying mechanisms of AF and the effect of inflammation targeting compounds in the development of atrial arrhythmias through phenotype-rescue screening.

In this webinar you will:

• Learn how human iPSC technology can be utilized for in vitro modeling of atrial fibrillation

• Gain insights into possible novel mechanisms underlying the onset of atrial fibrillation

• Discover new drug treatment possibilities for inflammation related arrhythmia treatment